Full Text View
Tabular View
No Study Results Posted
Related Studies
A 10-Week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (1)
This study has been terminated.
( Please see Detailed Description for termination reason. )
First Received: April 8, 2008   Last Updated: June 18, 2009   History of Changes
Sponsored by: Pfizer
Information provided by: Pfizer
ClinicalTrials.gov Identifier: NCT00658008
  Purpose

This is a 10-week trial that evaluates the efficacy and safety of PD 0332334 in subjects, ages from 18 to 65, with generalized anxiety disorder.


Condition Intervention Phase
Generalized Anxiety Disorder
 Drug: PD 0332334
Drug: Paroxetine
Drug: Placebo
 Phase III

Study Type: Interventional
Study Design: Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Parallel Assignment, Safety/Efficacy Study
Official Title: A Phase 3, Randomized, Double-Blind, Parallel Group, 10-Week Placebo Controlled Fixed Dose Study Of PD 0332334 And Paroxetine Evaluating The Efficacy And Safety Of PD 0332334 For The Treatment Of Generalized Anxiety Disorder

Resource links provided by NLM:

MedlinePlus related topics: Anxiety
Drug Information available for: Paroxetine Paroxetine hydrochloride Paroxetine Mesylate
U.S. FDA Resources

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • The efficacy of PD 0332334 in the treatment of GAD will be measured by the change in the Hamilton Anxiety Rating Scale (HAM-A) total scores from baseline observed following 8 weeks of double-blind treatment. [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • The safety and tolerability of PD 0332334 in subjects with GAD will be monitored in this study [ Time Frame: 8 weeks ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Worsening and improvement from baseline to week 8 on the changes in the Sexual Functioning Questionnaire (CSFQ) [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • Response rate on the patient-rated PGI-C at week 8 [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • Change from baseline to week 8 on the Sheehan Disability Scale subscales [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • Change from baseline in the somatic subscale score of the HAM-A (items 7 - 13) [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • Response rate on the HAM-A at week 1 and week 8 [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • Response rate on the clinician-rated CGI-I ate week 1 and week 8 [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • Change from Baseline in the psychic subscale score of the HAM A (Items 1- 6 and 14) at Week 8 [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • Change from Baseline to Week 1 on the Medical Outcomes Study Sleep Scale (MOS SS) Sleep Problems Index II [ Time Frame: 1 week ] [ Designated as safety issue: No ]
  • Change from Baseline to Week 8 on the Medical Outcomes Study Sleep Scale (MOS SS) Sleep Problems Index II [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • Change from baseline in the HAM-A total score at weeks 1, 2, 4, and 6 [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
  • Change from baseline in the 17-item HAM-D total score at weeks 1, 2, 4, and 8 [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • Change from Baseline to Week 8 on the Medical Outcomes Study Sleep Scale subscales [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • Remission rate based on the HAM A at Week 8 [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • Change from baseline in CGI-S at week 8 [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • Change from baseline to week 8 in the QLesQ General Activity Score [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • The "Week 1 Sustained Responder" rate based on the HAM A (where "Week 1 Sustained Responders" are defined as subjects with a 50% or greater improvement from baseline on the HAM A total score at Week 1 that is sustained until the Week 8 visit) [ Time Frame: 1 week ] [ Designated as safety issue: No ]
  • Change from Baseline to Days 2 8 and Weeks 2, 4, 6, 8 on the DAS A (total score) [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • Change from baseline to week 8 on the Sheehan Disability Scale (SDS) total score [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • Change from baseline to Days 2-8 and weeks 2, 4, 6 and 8 on the GA-VAS (diary) [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • Average (across the week 1, 2, 4, 6 and 8 visits) HAM-A change from baseline score [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]

Enrollment: 501
Study Start Date: April 2008
Study Completion Date: March 2009
Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
PD 0332334 175 mg BID: Experimental Drug: PD 0332334
Capsules, oral, 175 mg BID, 8 weeks with 2 week taper
PD 0332334 225 mg BID: Experimental Drug: PD 0332334
Capsules, oral, 225 mg BID, 8 weeks with 2 week taper
PD 0332334 75 mg BID: Experimental Drug: PD 0332334
Capsules, oral, 75 mg BID, 8 weeks with 2 week taper
Paroxetine 20 mg QD: Active Comparator Drug: Paroxetine
Capsules, oral, Paroxetine 20 mg QD, 8 weeks with 2 week taper
Placebo BID: Placebo Comparator Drug: Placebo
Capsules, oral, placebo bid, 8 weeks with 2 week taper

Detailed Description:

Termination reason: On February 23rd 2009, a decision to terminate further development for PD 0332334 was communicated to investigators in this study.

The decision to terminate this study was not based on any safety concerns.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of GAD (Diagnostic and Statistical Manual IV [DSM IV], 300.02) as established by the clinician (psychiatrist or licensed clinical psychologist) who has interviewed the subject using all sources of data including the Mini International Neuropsychiatric Interview (MINI) for DSM IV Axis I disorders and other clinical information. Subjects with specific phobia(s) (as defined in DSM IV) or dysthymic disorder will be allowed in the study.
  • Subjects must have a HAM A total score ≥20 at the screening (V1) and randomization (V2) visits. Subjects must also have a Covi Anxiety Scale score of ≥9 and a Raskin Depression Scale score ≤7 at the Screening (V1) visit to ensure predominance of anxiety symptoms over depression symptoms.

Exclusion Criteria:

  • Subjects with evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, pancreatic, neurologic, active infections, immunological, or allergic disease (including drug allergies).
  • Any of the following current (within the past 6 months through the present) DSM-IV Axis I diagnosis: Major Depressive Disorder, Obsessive Compulsive Disorder, Panic Disorder, Agoraphobia, Posttraumatic Stress Disorder, Anorexia, Bulimia, Caffeine induced anxiety disorder, Alcohol or substance abuse or dependence unless in full remission for at least 6 months, Social Anxiety Disorder.
  • Any of the following past or current DSM-IV Axis I diagnoses: Schizophrenia, Psychotic disorder, Delirium, dementia, amnestic, and other clinically significant cognitive disorders, Bipolar or schizoaffective disorder, Cyclothymic disorder, Dissociative disorders.
  • Antisocial or borderline personality disorder.
  • Serious suicidal risk per the clinical investigator's judgment.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00658008

  Show 52 Study Locations
Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
To obtain contact information for a study center near you, click here.  This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party: Pfizer, Inc. ( Director, Clinical Trial Disclosure Group )
Study ID Numbers: A5361019
Study First Received: April 8, 2008
Last Updated: June 18, 2009
ClinicalTrials.gov Identifier: NCT00658008     History of Changes
Health Authority: United States: Food and Drug Administration

Keywords provided by Pfizer:
PD 0332334 phase 3 pivotal trial

Study placed in the following topic categories:
Neurotransmitter Agents
Anxiety Disorders
Mental Disorders
Psychotropic Drugs
Antidepressive Agents, Second-Generation
 Serotonin Uptake Inhibitors
Paroxetine
Antidepressive Agents
Serotonin

Additional relevant MeSH terms:
Neurotransmitter Uptake Inhibitors
Neurotransmitter Agents
Disease
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Psychotropic Drugs
Paroxetine
Serotonin Uptake Inhibitors
Pharmacologic Actions
 Pathologic Processes
Serotonin Agents
Anxiety Disorders
Mental Disorders
Therapeutic Uses
Antidepressive Agents, Second-Generation
Central Nervous System Agents
Antidepressive Agents

ClinicalTrials.gov processed this record on July 02, 2009



Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services